Abstract
A prospective study was undertaken to evaluate oral methotrexate pulsed therapy in 6 cases of Eales disease presenting with perivasculitis. Methotrexate was administered (7.5 mg weekly) for 3 months. The therapy was tolerated well, and retinal perivasculitis subsided in all cases. Five patients achieved excellent visual acuity—6/6 (20/20) or better. Elevated titers of C-reactive protein returned to normal after therapy. Six-month follow-up revealed no recurrence of the disease.
Similar content being viewed by others
References
Gieser SC, Murphy RP. Eales disease. In: Ryan SJ, ed. Retina. Vol 2: Medical retina. St Louis, Mo: Mosby-Year Book; 1994:1503–1507.
Kumar D, Saxena RC, Saxena S. Vitreous hemorrhage in Eales disease. Afro-Asian J Ophthalmol. 1995;13:109–112.
Saxena S, Kumar D, Singh VK, Rajasingh J. Immunological studies in Eales disease: a review. Afro-Asian J Ophthalmol. 1995;13:19–22.
Rengarajan K, Muthukkaruppan VR, Namperumalsamy P. Biochemical analysis of serum proteins from Eales' patients. Curr Eye Res. 1989;8:1259–1269.
Muthukkaruppan VR, Rengarajan K, Chakkalath HR, Namperumalsamy P. Immunological status of patients of Eales' disease. Ind J Med Res. 1989;90:351–359.
Sawhney R, Gupta A, Bansal RK, et al. Eales' disease: an autoimmune retinal disorder. Proc All India Ophthalmol Soc. 1992;50:461–464.
Biswas J, Rao NA. Epiretinal membranes in Eales' disease and other vascular retinopathies. Invest Ophthalmol Vis Sci. 1990;31 (suppl):369.
Badrinath SS, Biswas J, Sharma T. et al. Immunophenotyping of inflammatory infiltrates in epiretinal (ERM) and subretinal (SRM) membranes in Eales' disease. Invest Ophthalmol Vis Sci. 1992;33 (suppl):857.
Chauber BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: JG Mardman, Limbird LE. eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1233–1282.
Palmer HE, Stanford MR, Sanders MD, Graham EM. Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis. Eye. 1996;10:343–348.
Stanford MR, Graham EM, Kasp E, et al. A longitudinal study of clinical and immunological findings in 52 patients with relapsing retinal vasculitis. Br J Ophthalmol. 1988;72:442–447.
Howe LJ, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye. 1994;8:443–447.
Isaacs J, Dick A. Short term immunosuppressive therapy and long term immunoregulation: promises and problems [commentary]. Br J Ophthalmol. 1996;80:1035–1036.
Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotroxate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419–1423.
Meyer PA, Watson PG, Franks W, Dubord P. Pulsed immunosuppreasive therapy in the treatment of immunologically induced corneal and scleral disease. Eye. 1987;1:487–495.
Mime CA, Playfair JHL, Roitt IMR, et al. The innate defenses of the body. In: Medical Microbiology. St Louis, Mo: Mosby-Year Book; 1993:4.1–4.14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saxena, S., Kumar, D. & Kapoor, S. Efficacy of oral methotrexate pulsed therapy in eales disease. Ann Ophthalmol 32, 60–62 (2000). https://doi.org/10.1007/s12009-000-0014-5
Issue Date:
DOI: https://doi.org/10.1007/s12009-000-0014-5